Opinion|Videos|July 15, 2024
Atopic dermatitis Clinical Trial Endpoints
Author(s)Christopher G. Bunick, MD, PhD
An atopic dermatitis expert discusses the primary and secondary efficacy endpoints and treatment goals commonly assessed in clinical trials for moderate to severe atopic dermatitis.
Advertisement
Episodes in this series
- Please share primary and secondary efficacy outcomes/treatment targets routinely examined in atopic dermatitis clinical trials for moderate to severe atopic dermatitis.
- Is there consensus amongst experts on treatment targets?
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5